Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
Palisade Bio (PALI) announced the presentation of positive preclinical data from PALI-2108, an orally administered, colon-specific ...
Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused ...
5d
Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure Company ...
Individuals on immunosuppressants should discontinue them prior to patch testing, if at all possible, to avoid tarnishing the test results, according to updated guidelines from the North American ...
Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
Advanced therapies, medicines bring new hope for pulmonary hypertension patients: Dr Manisha Mendiratta: Shardul Nautiyal, Mumbai Saturday, February 8, 2025, 08:00 Hrs [IST] Dr Ma ...
Omeros Corporation (Nasdaq: OMER) today announced the availability on its website of materials accompanying two presentations ...
Ro dives into the link between winter and erectile dysfunction, including reasons why it happens and possible solutions.
Data presented at the 2025 Crohn's and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure Company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback